Issues
-
Cover Image
Cover Image
Chronic inflammation plays important roles at different stages of cancer development, including carcinogenesis, tumor invasion, and metastasis. In this study, expression of angiopoietin-like protein 2 (Angptl2), recently identified as a chronic inflammation mediator in skin tissues, is highly correlated with the frequency of carcinogenesis in a chemically induced skin squamous cell carcinoma (SCC) mouse model. Furthermore, expression of Angptl2 in tumor cells promotes not only tumor angiogenesis and lymphangiogenesis, but also the acquisition of mesenchymal invasive characteristics in tumor cells through activation of TGF-b/Smad signaling, resulting in worse outcomes. This image represents a significantly increased tumor angiogenesis in SCC of Angptl2 transgenic (K14-Angptl2) mice. For details, see the article by Aoi and colleagues on page 7502 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Meeting Report
Priority Report
Integrated Systems and Technologies
Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression
Microenvironment and Immunology
Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
Peptide-Conjugated PAMAM Dendrimer as a Universal DNA Vaccine Platform to Target Antigen-Presenting Cells
Molecular and Cellular Pathobiology
Angiopoietin-like Protein 2 Is an Important Facilitator of Inflammatory Carcinogenesis and Metastasis
Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression
Phosphorylation of Carbonic Anhydrase IX Controls Its Ability to Mediate Extracellular Acidification in Hypoxic Tumors
Prevention and Epidemiology
Genome-Wide High-Density SNP Linkage Search for Glioma Susceptibility Loci: Results from the Gliogene Consortium
Therapeutics, Targets, and Chemical Biology
Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in Cancers
Sorcin Induces a Drug-Resistant Phenotype in Human Colorectal Cancer by Modulating Ca2+ Homeostasis
Tumor and Stem Cell Biology
Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial–Mesenchymal Transition in Cancer
Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers
Letters to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.